Therapeutics Corporation

United Therapeutics is a U.S.-based commercial-stage biotechnology company focused on therapies for pulmonary hypertension, oncology, and organ replacement technologies. The company markets multiple approved products including Tyvaso, Remodulin, Orenitram, Unituxin, and Adcirca, with pulmonary hypertension products driving the majority of revenue. In parallel, it is advancing late-stage programs such as ralinepag for pulmonary arterial hypertension and expanding Tyvaso into idiopathic pulmonary fibrosis. United Therapeutics also invests heavily in organ manufacturing, xenotransplantation, ex vivo lung perfusion, and related logistics technologies intended to increase the supply of transplantable organs. The company operates as a public benefit corporation and combines a profitable rare-disease franchise with a longer-term regenerative medicine and transplant platform.